SPRO

0.742010.20%
EP

Esther P. Rajavelu

CEO, President, CFO, Chief Business Officer, Treasurer & Director

Ms. Esther P. Rajavelu serves as Chief Financial Officer at Spero Therapeutics Inc. since August 1, 2023 and also serves as its Treasurer since November 2023 and serves as its President and CEO since May 2, 2025 and serves as its Director since June 12, 2025. She serves as Chief Business Officer at Spero Therapeutics Inc. She served as Interim President and CEO since January 2024 until May 2, 2025 and had been its Chief Business Officer until May 02, 2025. She served as Chief Financial Officer & Treasurer of Fulcrum Therapeutics, Inc. since January 03, 2022 until April 21, 2023. She joined Fulcrum Therapeutics, Inc. in January 2022. She served as an Analyst and Executive Director at UBS Investment Bank, Research Division. Ms. Rajavelu was employed at the firm till November 2021 and led the coverage of US small and mid-cap biotech equities. Prior to joining the firm, she served as an Executive Director and Senior Analyst at Oppenheimer & Co. Inc. Research Division. She was employed at the firm from 2018 until 2020 and catered to biotech and specialty pharmaceuticals within healthcare sector as a part of equity research at the firm. Prior to this, Ms. Rajavelu was a Research Analyst and was part of the major and specialty pharmaceuticals equities research team at Deutsche Bank AG, Research Division, where she launched coverage on small and mid-cap companies. Ms. Rajavelu has life sciences advisory experience as a biotech investment banker at Bank of America Merrill Lynch and a strategy consultant focused on the Major Pharmaceuticals segment, prior to her transition to equities research in 2014. Ms. Rajavelu had a successful career on Wall Street, serving as a Senior Equities Research Analyst covering SMID-cap biotechnology companies at UBS, Oppenheimer and Deutsche Bank. Prior to her career in sell-side equities research, she spent several years as a healthcare investment banker. She focused on biotechnology transactions and also served as a Business Strategy Consultant at major pharmaceutical companies. She served as Debt Advisory at Ernst & Young Capital Advisors, LLC, a brokerage firm (EY Capital) since 2011 until 2014. She has years of biotech and pharmaceuticals industry experience and has been covering large cap and SMID-cap biotech and pharmaceuticals. She has life sciences sector experience combining equities research, investment banking, strategy consulting and most recently CFO operating experience. She has deep expertise in strategy, investor relations, financing and M&A in the pharmaceuticals and biotechnology sectors. Prior to investment banking, she was a strategy consultant at Towers Perrin focused on U.S. large pharmaceutical companies. The breadth of her company experiences includes Fortune 500, mid-cap companies and startups in the life sciences sector. She received a B.A. in Economics and International Relations from Wesleyan University and an M.B.A from The Wharton School at the University of Pennsylvania.

Positions